I was going to ask Alan about it. In the recent quarterly they mention that the supply is an easily scalable but that is a relative term. If the drugs are successful in achieving their endpoints, and the revenues and profits justify it either BP will acquire CU6 and build the backend given their global presence and reach, or other participants in the cyclotron/ rhoodotron may do so as well, ie if the demand is there the supply will come.
Research/Valuation, page-4
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.53 |
Change
-0.070(2.69%) |
Mkt cap ! $775.5M | |||
| Open | High | Low | Value | Volume |
| $2.59 | $2.60 | $2.53 | $652.8K | 256.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 200 | $2.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.59 | 14109 | 2 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.53 |
Change
-0.070 ( 2.40 %) |
||||
| Open | High | Low | Volume | ||
| $2.58 | $2.60 | $2.53 | 29022 | ||
| Last updated 15.59pm 26/04/2024 ? | |||||
| CU6 (ASX) Chart |